Mouse models of cancer play an important role in elucidating the molecular mechanisms that contribute to tumorigenesis. The extent to which these models resemble one another and their human counterparts at the molecular level is critical in understanding tumorigenesis. In this study, we carried out a comparative gene expression analysis to generate a detailed molecular portrait of a transgenic mouse model of IGFIR-driven lung cancer. IGFIR-driven tumors displayed a strong resemblance with established mouse models of lung adenocarcinoma, particularly EGFR-driven models highlighted by elevated levels of the EGFR ligands Ereg and Areg. Cross-species analysis revealed a shared increase in human lung adenocarcinoma markers including Nkx2.1 and Napsa as well as alterations in a subset of genes with oncogenic and tumor suppressive properties such as Aurka, Ret, Klf4 and Lats2. Integrated miRNA and mRNA analysis in IGFIR-driven tumors identified interaction pairs with roles in ErbB signaling while cross-species analysis revealed coordinated expression of a subset of conserved miRNAs and their targets including miR-21-5p (Reck, Timp3 and Tgfbr3). Overall, these findings support the use of SPC-IGFIR mice as a model of human lung adenocarcinoma and provide a comprehensive knowledge base to dissect the molecular pathogenesis of tumor initiation and progression.
Introduction
Lung cancer is the leading cause of cancer-related deaths worldwide [1] . Non-small cell lung cancer (NSCLC) represents the major form of the disease accounting for up to 85% of cases and can be broadly categorized into adenocarcinoma (ADC), squamous cell carcinoma (SCC) and large cell carcinoma (LLC) histological subtypes [2, 3] . ADC is the most frequently diagnosed form of NSCLC and is characterized by glandular differentiation, expression of thyroid transcription factor 1 (TTF1 also known as NK2 homeobox 1 or NKX2-1) and frequent mutations in KRAS or EGFR [2, 3] . SCC accounts for approximately 40% of NSCLC cases and can be distinguished from ADC by expression of p63 and basal keratins while LLC is less prevalent and diagnosed when features of ADC or SCC are absent [2, 3] .
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Mouse models have been widely employed to explore the biology of human malignancies including lung cancer [4] . Models that permit transformation of normal cells in situ, for example those that rely on chemical or genetic methods of tumor initiation, have been of particular value. Given the link between smoking and lung cancer risk, chemically induced mouse models of lung cancer have been developed through administration of tobacco-related carcinogens such as urethane and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) [5] . Resulting tumors harbor features of NSCLC with adenoma (AD) or ADC histopathology and frequently harbor activating Kras mutations. More precise manipulation of candidate oncogenes and tumor suppressors have been achieved with genetically engineered mouse models (GEMMs). For instance, promoters that drive transgene expression to specific cell lineages including surfactant protein-C (SPC) which directs expression to type II alveolar cells (AT2) and Club cell secretory protein (CCSP) which targets non-ciliated Club cells allow for spatial control of transgene expression [6] . In addition, temporal control can be achieved with the Cre-loxP and tetracycline (tet) inducible systems [6] . Together, these advances have allowed for the development of more complex and accurate models of the disease.
The vast majority of GEMMs developed to date resemble lung ADC [4] . Given the frequent occurrence of KRAS mutations in human lung ADC, those based on mutant versions of Kras have been widely studied [4, 7] . In the Kras LA2 model, spontaneous recombination of a latent mutant Kras allele (G12D) leads to the formation of lung tumors with complete penetrance and features of AD/ADC [8] . To allow for better control over tumor latency and multiplicity, conditional models of Kras-mutant lung cancer incorporating Cre-and/or tet-inducible alleles have also been developed [9] [10] [11] . In addition to their use in exploring the molecular mechanisms of tumor initiation and progression [9, 10, 12, 13] , Kras-mutant models have been valuable in the pre-clinical setting and have led to the identification of modifiers of treatment response [14, 15] and therapeutic strategies to specifically target Kras-mutant cancers [16] . A series of tet-inducible models of mutant EGFR-driven lung ADC have also been generated [17] [18] [19] . Overexpression of an EGFR tyrosine kinase domain mutant (L858R) that is sensitive to the EGFR TKI erlotinib led to the rapid development of tumors that phenotypically resembled the human disease [17] . In contrast, mice in which an erlotinib resistant mutant (T790M) is overexpressed either alone or in combination with L858R resulted in tumor formation after long latency. These mutant strains have been particularly valuable for identifying novel therapeutic targets to overcome EGFR TKI resistance [18, 20] .
In addition to Kras and Egfr, the pro-tumorigenic role of other molecular alterations found in human lung ADC have been established in mice including the Ras signaling mediator cRaf-1 [21] and the pro-inflammatory transcriptional activator Stat3 [22] . Furthermore, recent advances in our understanding of lung cell lineage genes as well as genomic profiling have led to the development of models that resemble other subtypes of NSCLC. These models include adenosquamous carcinomas driven by combined loss of Pten and Smad4 [23] , mucinous adenocarcinomas resulting from overexpression of Kras on a Nkx2.1 haploinsufficient background [24] and SCC following loss of the key tumor suppressors Lkb1 and Pten [25] .
Understanding the degree to which mouse models of lung cancer resemble the human disease is crucial for the accurate translation of findings between species. While the Kras LA2 GEMM and urethane-induced models have been shown to share a common gene expression profile with human lung ADC [26, 27] whether models carrying oncogenic drivers other than Kras reflect the molecular changes found in human lung ADC remains unclear. We have previously described a doxycycline inducible mouse model of lung cancer, SPC-IGFIR, in which the human type-I insulin-like growth factor receptor (IGFIR) is overexpressed AT2 cells via the SPC promoter [28] . These mice develop nodular lesions that resemble AD and ADC with a latency of approximately 9 months of age. Given that hyper-activation of IGFIR has been observed in NSCLC patient specimens [29] and disruption of IGFIR signaling with monoclonal antibodies or small molecules inhibits tumor growth in vivo [30, 31] , a better understanding of the molecular features of this model is warranted. Here, we present an mRNA and miRNA comparative analysis of the SPC-IGFIR model with other established mouse models and human lung cancers.
Materials and methods

Mice
The generation of SPC-IGF1R transgenic mice on an FVB background has been previously described [28] . To induce transgene expression, mice were fed chow supplemented with 2g/kg doxycycline (Harlan/Envigo) beginning at 21 days of age. For tissue collection, mice were sacrificed by CO 2 asphyxiation. Mice were maintained following the Canadian Council for Animal Care guidelines and ethical approval was provided by the Animal Care Committee at the University of Guelph.
RNA-Seq, miRNA-Seq and data analysis
Total RNA was extracted using the miRVana miRNA Isolation Kit (ThermoFisher, USA Clustering and heatmap visualization. For hierarchical clustering and/or heatmap generation of RNA-Seq data, raw counts were first normalized for library size using the estimateSizeFactors function in the DESeq2 package[36]. The normalized counts were then log2 (plus 1 pseudo-count) transformed, gene-wise median centered and then clustered and visualized using the pheatmap package (v1.0.8) in R.
Differential gene expression analysis. For RNA-Seq datasets, differentially expressed genes were identified with DESeq2 (version 1.10.1) [36] . Raw count data for ADC, SCC and corresponding normal tissues from the LUAD and LUSC TCGA datasets was downloaded from GEO (GSE62944). Identification of differentially expressed genes from mouse model microarray datasets was carried out using the GEO2R tool for GEO datasets or limma [37] for datasets from EMBL-EBI Array Express (E-MEXP-1137) and the Lkb1/Pten model (kindly provided by Dr. Paul Hammerman). For miRNA analysis of the LSL-Kras G12D model, p-values and isomiR (5p/3p-arm level) expression were not reported in the original publication [38] . Therefore, raw FASTQ files were downloaded from SRA (SRP017615), and processed and analyzed as above. Chromosome locations of miRNAs were extracted from the mmu.gff file provided by miRBase v21. Gene set enrichment analysis (GSEA) and gene annotation enrichment. GSEA was carried out using the pre-ranked tool [39] as recommended for RNA-Seq data (https://software. broadinstitute.org/cancer/software/gsea/wiki/index.php/FAQ). Genes were ranked using the signed log10 transformed p-value. The following parameters were used: number of permutations = 1000, enrichment statistic = weighted, max gene set size = 500, min gene set size = 8. Gene-sets with an FDR value < 0.001 were considered significant. Gene-sets were obtained from http://baderlab.org/GeneSets and the MSigDB (v5.0). GO and KEGG enrichment analysis of gene lists were carried out using DAVID 6.8 [40] . Cytoscape and Enrichment Map [41] were used for visualization. qPCR qPCR was carried out as previously described [42] . Primers were obtained from Bio-Rad (CA, USA) and relative quantification of gene expression was determined using the ΔΔCq method with Hprt and Ywhaz reference genes.
Primary lung tumor cell isolation and magnetic activated cell sorting
Primary tumor tissue from SPC-IGF1R mice was dissected, minced and placed in 4 ml of 1mg/ml collagenase/dispase solution (Sigma-Aldrich) in RPMI-1640 (GIBCO) with shaking at 220rpm for 1.5hrs at 37˚C. The digestion solution was replaced with fresh enzymes after 45 minutes. Digested tissue was then centrifuged for 5 min at 350xg, treated with 2U/ul of Dnase I (Sigma-Aldrich) and passed through a 40μM strainer. Contaminating red blood cells were then removed with RBC lysing buffer (Sigma-Aldrich) and cells were resuspended in HBSS supplemented with 2%FBS (GIBCO). Separation of epithelial and non-epithelial cells (CD45, CD31, Tert119 and BP-1) was carried out using the EasySep Mouse Epithelial Enrichment Kit (1:10 epithelial enrichment cocktail, 1:20 biotin selection cocktail and 1:10 magnetic particles) and EasySep Magnet (STEMCELL Technologies). To further enrich for tumor cells, a biotinylated anti-human IGF1R antibody (1:10, clone REA271, Miltenyi Biotech) was added to the epithelial enriched fraction for 30 min on ice followed by positive selection and separation as above.
Statistics
Statistical analysis and visualization was performed using R-3.4.2 and Prism 5 (Graphpad, La Jolla, CA) unless otherwise stated. ANOVA followed by post-hoc Tukey test was used to compare means from multiple groups while unpaired or paired student's t-test was used for the comparison of two means. Error is represented by standard error of the mean (s.e.m). Statistical significance is noted as p < 0.05.
Results
Gene expression profiling of murine IGFIR-driven lung tumors
To characterize IGFIR-driven lung tumorigenesis at the gene expression level, RNA-Seq was carried out on tumors from SPC-IGFIR transgenic mice and normal lung tissue obtained from non-transgenic animals ( Fig 1A) . As expected, unsupervised hierarchical clustering of the normalized reads revealed two distinct groups separating the tumor and normal samples (Fig 1B) . Differential gene expression analysis identified 4991 genes with altered expression of which a greater proportion were down-regulated ( Fig 1C and Fig 1D and S1 Table) . Top up-regulated genes included the IGFIR/IR adaptor Grb14, the serine-threonine kinase Stk39 and the EGFR ligands Ereg and Areg while the most significantly down-regulated genes included those expressed in normal lung cell populations including Rspo4, Myl3 and Reg3g. As expected, sequence read alignment against a mouse-human hybrid reference genome confirmed high levels of the human IGFIR transgene but not endogenous murine Igf1r (Fig 1E) .
To identify biological pathways associated with these changes in gene expression, we carried out gene-set enrichment analysis (GSEA) [39] . Using a large collection of gene-sets (~19,000) representing diverse pathways, tumors were enriched for processes related to cell division, cell 
Marker expression of murine IGFIR-driven lung tumors
Tumors from SPC-IGFIR mice feature an adenoma/adenocarcinoma histology [28] . Consistent with this, IGFIR-driven tumors expressed established markers of human lung adenocarcinoma [44] including Nkx2-1 and Napsa while the expression levels of marker genes associated with lung squamous cell carcinoma (Trp63 and Krt5) or mucinous adenocarcinoma (Muc5ac, Muc5b) were either lower than normal lung tissue or unchanged ( Fig 1F) . In addition, tumors contained elevated levels of the AT2 cell lineage markers including (Sftpa1, Sftpb, Sftpd) while the club cell marker Scgb1a1 (also known as Cc10 or Ccsp) was significantly reduced. These findings validate the pathohistology of IGFIR-driven tumors and support AT2 cells as the tumor cell of origin using the SPC-rtTA driver line.
Comparative gene expression analysis of murine lung tumor models
To explore how the gene expression profile of SPC-IGFIR mice related to other mouse models of lung cancer, we assembled a collection of publically available microarray-based gene expression datasets that contained both tumor and normal lung samples and were representative of diverse lung tumor subtypes ( Table 1) . As a measure of similarity, we computed the spearman correlation coefficient of log2 fold-changes between genes differentially expressed in each mouse model with the corresponding genes in the SPC-IGFIR model. This analysis revealed a stronger correlation between tumors from SPC-IGFIR mice with models of AD/ADC (spearman's rho = 0.46-0.82) than the other tumor subtypes (spearman's rho = -0.0054-0.18). An exception was the moderate correlation of IGFIR-driven tumors and other AD/ADC models with the Rb/p53 double knockout SCLC model (spearman's rho = 0.54) which may be reflective of the high expression of cell cycle associated genes.
Tumors from SPC-IGFIR mice displayed the strongest similarity with the C/L858R model (C/L) [18] ; a doxycycline inducible model characterized by overexpression of the EGFR kinase domain mutation L8585R (c.2573T>G) (Fig 2A) . Gene overlap analysis identified a total of 1487 differentially expressed genes altered in the same direction between the two models ( Fig  2B) . Plotting of the log2 fold changes of these shared genes revealed high expression of several genes implicated in human lung cancer including the Notch inhibitor Dlk1 [38] ,the matrix metalloprotease Mmp12 [47] as well as the EGFR ligands Ereg and Areg which were the two most highly expressed genes in both models (Fig 2C) .
The dramatic upregulation of Ereg and Areg mRNA expression in IGFIR-driven tumors compared to normal lung tissue was confirmed by qPCR ( Fig 2D) . In addition, significant upregulation of Ereg and/or Areg was also identified in a number of other AD/ADC models ( Fig  2E) . To gain insight into whether tumor cells themselves are the primary source of Ereg and Areg, we used magnetic cell sorting to isolate IGFIR + tumor and non-epithelial lineage cells regulation of Areg and Ereg in tumor cells though changes in Ereg were not statistically significant. Taken together, these findings indicate that diverse mouse lung tumor subtypes are associated with distinct gene expression profiles and that IGFIR-driven tumors share molecular features with established models of AD/ADC characterized at least in part by a deregulated EGFR pathway.
Cross-species gene expression comparison with human NSCLC
Given the similarity of IGF-IR driven tumors with mouse lung ADC we next investigated the extent to which the gene expression profile of IGFIR-driven lung tumors mimic the human disease. RNA-Seq data of human ADC [48] , SCC [49] and normal lung tissues were obtained from the TCGA dataset. Differentially expressed genes were identified and the spearman correlation coefficient of log2 fold changes with the orthologous murine genes in the SPC-IGFIR dataset was then computed. In contrast to the comparative mouse model analysis, the similarity of IGFIR-driven tumors with human ADC was more moderate (spearman's rho = 0.32) but higher than SCC (spearman's rho = 0.23) (Fig 3A) . Gene overlap analysis of the differentially expressed genes in human lung ADC and murine IGFIR-driven tumors identified 1022 genes with the same change in direction representing 32% of genes altered in human ADC (Fig 3C  and S2 Table) . Gene Ontology (GO) and KEGG pathway analysis with Database for Annotation, Visualization and Integrated Discovery (DAVID) [40] revealed the shared upregulated genes were enriched for terms largely related cell cycle processes while shared down-regulated genes were associated with normal lung function (S3 Fig). Terms and pathways unique to IGFIR-driven tumors consisted mainly of processes related to metabolic processes.
To examine the relevance of these shared mouse and human genes to cancer we mined the ONGene [50] and TSG2.0 [51] databases and identified 31 and 80 genes with purported Fig 3B) . GO enrichment analysis confirmed the biological roles of these genes in cancer related processes including cell cycle and transcriptional regulation as well as migration and Wnt and MAPK signaling (Fig 3C and  Fig 3D) . Genes upregulated in both IGFIR-driven tumors and human ADC included those with reported roles in lung cancer such as AURKA, SOX4, RET, MET and ETV4 while those downregulated in both species included KLF4, TIMP3, CAV1 and LATS2. Of note, a subset of these SPC-IGFIR and human lung ADC shared genes were unique to the SPC-IGFIR model when compared to tumors from C/L858R mice with the transcriptional regulator DLX5 and the secreted Wnt antagonist SFRP5 displaying the greatest positive and negative fold changes respectively (S4 Fig) .
Deregulated miRNA-mRNA expression in IGFIR-driven lung tumors
MicroRNAs (miRNAs) represent a class of small non-coding RNA molecules (~22nt) that provide an additional layer of gene expression regulation and have been strongly implicated in cancer pathogenesis [52] . Thus, to complement our mRNA analysis, we also carried out small RNA sequencing on tumors from SPC-IGFIR mice and normal lung tissue. Differential expression analysis identified 55 up-regulated and 66 down-regulated miRNAs (fold-change �2, FDR<0.05, Fig 4A and S3 Table) , many of which have been implicated in cancer [52] . The top up-regulated miRNAs included those with known oncogenic properties (oncomiRs) including miR-21a-5p/3p, miR146b-5p/3p, miR-210 and miR-31-5p and regulators of the epithelial-state (miR200b/a/429 and miR-200c/141). Down-regulated miRNAs included those with known tumor suppressive activity including miR-92a-3p, miR-99a-5p and miR-10a-3p. To identify potential miRNA target genes, we integrated the miRNA and mRNA datasets and then accessed multiple databases of predicted and validated miRNA-mRNA interaction using the multiMiR package [53] (S4 Table) . Interestingly, pathway analysis revealed these potential miRNA targets were associated with ErbB2 signaling involving ligands (Ereg, Btc, Nrg1, Nrg2), receptors (Egfr, Erbb2, Erbb3, Erbb4), adaptor proteins (Shc1, Shc4) and the downstream kinases Kras, Akt3 and Mapk10 ( S5 Fig) . Next, we focused on "validated" miRNA-mRNA interactions and further narrowed the list of target genes to those with oncogenic or tumor suppressive functions through mining of the ONGene [50] and TSG2.0 [51] databases (Fig 4B) . This led to the identification of 30 miRNA-mRNA interaction pairs ( Fig  4C) involving known tumor suppressor targets of miR-21a-5p (Reck, Timp3 and Tgbr3) and miR-31-5p (Lats2 and Dmd) as well as oncogenic targets of miR-143-3p (Kras), miR-145-5p (Klf5, Kras) and miR-1195-5p (Met).
Comparative miRNA expression
In contrast to the large number of high-throughput gene expression studies carried out on mouse models of lung cancer, few genome-wide miRNA profiles have been described. Although Kras-driven tumors exhibited only a modest correlation with SPC-IGFIR mice at the mRNA level, the availability of miRNA-Seq data led us to explore potential similarities and differences in miRNA expression between these two models. First, we re-analyzed this dataset A significant number of miRNAs are located in genomic clusters [54] and in the Kras G12D model, the majority of differentially expressed miRNAs were reported to be located in a cluster at the Dlk1-Dio3 locus on chr12qF1 [38] . We confirmed these results in our re-analysis of this dataset but in contrast to Kras
G12D
-driven tumors, we found differentially expressed miRNAs in the SPC-IGFIR model were located in clusters along multiple chromosomes with a complete absence of altered miRNAs found on chr12 (S6 Fig) . Therefore, these results further demonstrate that despite sharing similar histological features, murine lung ADCs initiated by different oncogenic drivers may be associated with distinct molecular changes including those at the miRNA level.
Finally, we compared the miRNA expression profile of IGFIR-driven tumors with human lung ADC using miRNA-Seq data of tumor and normal tissue from the TCGA-LUAD dataset [48] (S5 Table) . Similar to the mRNA comparative analysis, a modest correlation was found (spearman's rho = 0.36) between differentially expressed miRNAs identified in human ADC and species conserved orthologous miRNAs in the SPC-IGFIR model (Fig 5A) . A total of 20 miRNAs with coordinated changes in expression across species were identified including miR-21-5p, miR-31-5p, miR-210-3p and miR-490-3p (Fig 5B and Fig 5C) . A subset of miRNAs also exhibited discordant expression including upregulation of miR-184-5p in IGFIR-driven tumors and increased expression of miR-9-5p, miR-196a-5p miR-653-5p in human ADC. Integration of the human miRNA-mRNA datasets with multiMiR (S6 Table) followed by mining of the ONGene [50] and TSG2.0 [51] databases identified 6 'validated' interaction pairs common between IGFIR-driven tumors and human ADC involving miR-21-5p (RECK, TIMP3, TGFBR3), miR-31-5p (LATS2) and miR-150-5p (TNS4) (Fig 5D) . A number of shared 'predicted' miRNA targets that may also be involved in IGFIR-mediated tumorigenesis and human ADC included the tumor suppressors deleted in liver cancer 1 (DLC1), adherens junction associated protein 1 (AJAP1) and glypican-3 (GPC3) (Fig 5E) .
Discussion
Here we report on the gene expression profile a mouse model of IGFIR-driven lung cancer. The goal of this study was to not only understand the molecular changes associated with IGFIR-driven tumorigenesis but to also assess the relevance of these alterations in the context of other established mouse models of lung cancer and the human disease. In the mouse-tomouse comparison, we found similarities with models of lung ADCs initiated by different oncogenic drivers, particularly those driven by mutant versions of EGFR. This is perhaps not surprising given that both IGFIR and EGFR are receptor tyrosine kinases (RTKs) that activate common signaling pathways including PI3K/AKT and Ras/MAPK [55] . Despite the similarities in gene expression between these models, there are clear differences in the oncogenic potential of IGFIR and EGFR in the mouse lung as tumor onset occurs much more rapidly in the mutant EGFR models (4-8 weeks versus 8-9 months in SPC-IGFIR mice). This dramatic Upregulation of the EGFR ligands Ereg and/or Areg was a common feature between IGFIRdriven tumors and mouse models of lung ADC. Elevated levels of these ligands has been previously noted in a subset of these mouse models [18, 21, 56] . Interestingly, loss of Ereg reduced tumor burden in a carcinogen induced mouse model of lung cancer [56] but was not required for intestinal tumorigenesis in APC min mice [57] suggesting a tumor-type specific role for this ligand. In human lung cancer, EREG and AREG mRNA or protein levels are elevated in a subset of NSCLC cell lines [58, 59] as well as NSCLC specimens and predict poor survival [59, 60] . Expression of EREG mRNA has also been found to be higher in adenocarcinomas versus squamous cell carcinomas [59] . Although classically thought of as epithelial specific molecules that regulate EGFR signaling via an autocrine loop, production of EREG and AREG has been detected in stromal cells including normal and cancer associated fibroblasts [61] [62] [63] and various immune cell populations [64, 65] . Using magnetic cell sorting and qPCR we also observed expression of Ereg and Areg in the tumor and non-epithelial cell compartment though levels were significantly higher (Areg) or trended towards being higher (Ereg) in the tumor cell population. A recent computational analysis of tumor-stroma interactions in murine Kras-driven lung tumors identified an Ereg-Egfr autocrine signaling axis in tumor cells and an Areg-Egfr pathway of monocyte-tumor cell crosstalk [66] . Given that these ligands may represent alternative targets for therapeutic inhibition of EGFR signaling in lung cancer [66] and the growing importance of immune effectors in lung cancer pathogenesis, the specific cell types that express Ereg and Areg and their functional role in tumorigenesis are areas of interest in the future use of the SPC-IGFIR model. In a cross-species analysis, we observed a more modest similarity in gene expression (32% of differentially expressed genes) between IGFIR-driven tumors and human lung ADC compared to those computed for mouse models of lung ADC. This finding was not unexpected given the significant molecular heterogeneity evident in the majority of human solid cancers including lung ADC [3, 48, 67] . These results are also consistent with a cross-species study of urethane-induced tumors from Stearman and colleagues in which an overlap of only 409 genes (representing approximately 15% of altered genes in human lung ADC) was observed [26] . Nevertheless, the utility of this model was validated as conserved changes in genes relating to glycolysis, cell cycle and the eicosanoid pathway were discovered. In addition, cross-species analysis of the Kras LA2 model revealed approximately 12% of differentially expressed genes were shared with human lung ADC and when combined with GSEA led to the identification of a gene signature of human KRAS-mutant tumors which could not be identified from the analysis of human KRAS-mutant alone [27] . Thus, while mouse lung cancer models may not recapitulate all of the gene expression changes observed in human tumors, a subset of conserved alterations are often present that can provide important insight into the disease. In this study, we focused on the identification of species conserved changes in cancerrelated genes resulting in the identification of a number of alterations with oncogenic and tumor suppressive properties that were altered across species. Of interest is the shared upregulation of DLX5 (Distal-less Homeobox 5), which did not appear to be altered in the C/L858R EGFR-driven model. DLX5 is one of six DLX family members expressed during embryonic development [68] but has also been implicated in a number of cancers [69] [70] [71] [72] . In NSCLC, DLX5 has been reported to be overexpressed at the mRNA and protein level, and correlated with tumor size and poor prognosis [72] . At the mechanistic level, the pro-tumorigenic functions of DLX5 have been shown to involve positive regulation of the MYC promoter in human lung cancer cells [70] as well as the IRS2 promoter, an IGFIR adapter protein, in ovarian cancer cell lines [69] . Whether DLX5 or its downstream targets are required for lung tumor initiation and maintenance in vivo is unknown but our data suggests the SPC-IG1R model may be useful to test this hypothesis. Deregulated miRNA expression regulates a variety of biological processes related to cancer pathogenesis [52] . Integration of miRNA-mRNA data from IGFIR-driven tumors revealed regulation of pathways including ErbB signaling. In human lung ADC, miRNAs have also been shown to regulate the EGFR pathway and may have potential as biomarkers for predicting anti-EGFR therapeutic response [73] . In a cross-species analysis, we identified miRNAs commonly deregulated in lung ADC including the well-studied oncomiR miR-21-5p. Elevated miR-21 is a defining feature of multiple cancers including lung ADC and is observed more frequently in patients with EGFR mutant disease [73] . The pro-tumorigenic properties of miR-21 have been linked with suppression of negative regulators of Ras signaling including Spry1 and Spry2 [74] . Here, we identified the validated miR-21 targets Reck, Timp3 and Tgfbr3 were deregulated in IGFIR-driven tumors which was also conserved in human lung ADC. While miR-21 and miR-31 have been shown to play a direct role in regulating Kras-driven lung tumorigenesis in vivo [74, 75] , whether they play a similar role in lung cancer driven by other oncogenic drivers, including IGFIR, remains unknown. Given that few miRNAs have been directly validated in lung cancer initiation and progression in vivo, the results of this study provide a framework to address the functional role of less well studied miRNAs in lung cancer.
A common theme of this study was the identification of a potential role for the ErbB pathway in IGFIR-driven tumors. EGFR and IGFIR are often co-expressed in patient samples [76] and up-regulation of IGFIR has been shown to mediate EGFR TKI resistance [77] . Pre-clinical studies also demonstrated greater anti-tumor activity with dual targeting of EGFR and IGFIR though clinical translation was not successful [78] . As the clinical failure of anti-IGFIR therapeutics is thought to be due in part to poor patient selection [79] , the potential efficacy of combined targeting both pathways remains uncertain. Thus, the SPC-IGFIR model may provide a valuable platform to dissect co-operation between EGFR and IGFIR and also serve as a preclinical model to test therapeutic blockade of these signaling pathways.
In summary, we have presented a detailed overview and inter-and cross-species comparative mRNA and miRNA gene expression analysis of IGFIR-driven lung cancer. The comprehensive molecular profiling presented in this study will facilitate future investigations into multiple aspects of tumor initiation and progression and hopefully provide insight towards the identification of rationale therapeutic targets for lung cancer. 
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